Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression  by Dudeja, Vikas et al.
ORIGINAL ARTICLE
Neoadjuvant chemoradiotherapy for locally advanced pancreas
cancer rarely leads to radiological evidence of tumour regression
Vikas Dudeja1, Edward W. Greeno2, Sidney P. Walker3 & Eric H. Jensen1
Departments of 1Surgery, 2Medical Oncology and 3Radiology, University of Minnesota, Minneapolis, MN, USA
Abstract
Background: Neo-adjuvant chemo-radiotherapy has been proposed to improve resectability of locally-
advanced pancreatic cancer (LAPC). However, the ability of neo-adjuvant therapy to induce radiological
tumour regression has not been reported.
Methods: Pre- and post-treatment computed tomography (CT) scans of patients undergoing neo-
adjuvant chemo-radiotherapy for LAPC were reviewed. LAPC was sub-classified into borderline resect-
able disease [180° involvement of the superior mesenteric artery (SMA); short-segment encasement/
abutment of the common hepatic artery; or tumour-associated deformity, abutment or short-segment
occlusion of the superior mesenteric vein (SMV)/ portal vein (PV) that was amenable to vascular resection
and reconstruction] and locally advanced un-resectable pancreatic cancer (vascular involvement more
than that described for borderline resectable pancreatic cancer). The radiological response and surgical
resection rates were assessed.
Results: Sixteen patients received neo-adjuvant therapy for LAPC during 2005–2008. Regression of
major vascular involvement, i.e. un-encasement or regression of abutment of any involved vessels was
not observed in any patient. Pre- and post-treatment tumour densities were not statistically different. Fifty
per cent of patients with borderline resectable disease and none of the patients with locally advanced
un-resectable pancreatic cancer eventually underwent surgical resection.
Conclusion: Neo-adjuvant treatment does not induce radiological tumour regression of LAPC with
major vascular involvement. Patient selection for neo-adjuvant trial enrolment should remain focused on
borderline disease which may have a potential for surgical resection.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related
mortality in the United States.1 The all-stage 5-year survival rate
for this cancer is a dismal 5% which has largely unchanged over
three decades.1 Surgical resection offers the only opportunity of a
cure. However, only 10–20% of patients present early enough to
be considered a candidate for curative surgery.2 Forty per cent of
patients have metastatic disease at presentation and are mainly
considered for palliative therapy. The remaining 40–50% have
locally advanced disease which is not amenable to immediate
surgical resection,2 especially without any additional therapy.
Given that surgical extirpation is the only chance of a cure,
neo-adjuvant therapy has been used to induce tumour regression
and convert locally advanced, non-metastatic disease to one that is
surgically resectable, thus potentially improving outcomes. After
neo-adjuvant therapy for locally advanced pancreatic cancer, sur-
gical resection rates of 1–81%3–6 have been reported in literature.
This wide variation in the reported rates of resection after neo-
adjuvant therapy could be explained by the use of a non-standard
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definition of locally advanced pancreatic cancer and a varying
extent of surgical resection. Increasing the understanding of this
problem has led to the emergence of consistent definitions of
locally advanced pancreatic cancer.7–9 Furthermore, the best way
to monitor a response to neo-adjuvant therapy is also not estab-
lished. Typically, patients undergoing neo-adjuvant therapy for
locally advanced pancreatic cancer undergo serial imaging [e.g.
computed tomography (CT) scan] to evaluate a response and
resectability. However, the rate of radiological responses to neo-
adjuvant therapy has not been reported before. The aim of the
present study was to evaluate the radiological response of patients
with locally advanced pancreatic cancer to neo-adjuvant therapy.
Methods
Patient selection and treatment algorithm
Patients included in this study were treated with a combination of
cisplatin, interferon-a, fluorouracil (5-FU) and radiation based
on the phase II treatment protocol for locally advanced pancreatic
cancer from 2005–2008 but included patients treated off protocol
as well. Sixteen patients diagnosed with locally advanced pancre-
atic adenocarcinoma from 2005–2008 were included. Locally
advanced pancreatic cancer was defined as pancreatic cancer with
vascular involvement precluding immediate surgical resection
and was further subdivided into those with ‘Borderline Resec-
table Pancreatic Cancer’8 and those with ‘Locally Advanced
Un-resectable Pancreatic Cancer’. Borderline resectable pancreatic
cancer was defined as the absence of distant metastasis and one or
more of the following: (i) tumor-associated deformity of the supe-
rior mesenteric vein (SMV) and portal vein (PV); (ii) abutment of
the SMV or PV 180°; (iii) short-segment occlusion of the SMV
or PV amenable to resection and venous reconstruction; (iv)
short-segment involvement of the hepatic artery or its branches
amenable to resection and reconstruction; and (v) abutment of
the SMA <180°.10 ‘Locally advanced un-resectable’ disease was
defined as patients who were un-resectable owing to vascular
involvement but the disease was more extensive than as defined
for borderline resectable disease.
All patients had histological confirmation of pancreatic adeno-
carcinoma before initiation of interferon-based chemo-radiation
(interferon-a, cisplatin, 5-FU and radiation). Five out of 16
patients were explored before neo-adjuvant therapy with the
intent of surgical resection but were found to be un-resectable and
were subsequently included in the neo-adjvuant therapy protocol.
A pancreas protocol CT was obtained before initiation of neo-
adjuvant therapy. After therapy patients were restaged by a pan-
creas protocol CT scan and a resection was re-considered in a
multi-disciplinary conference. All except two patients had carbo-
hydrate antigen (CA) 19-9 measured before initiation of chemo-
therapy and after completion of chemotherapy. All pathological
specimens underwent standard pathological examination. The
bile duct margin, pancreatic margin and SMA margin were sys-
tematically analysed.
Data collection and statistical analysis
The study was approved by Institutional Review Board at the
University of Minnesota. Patient demographics and CA 19-9
levels (before initiation of chemo-radiation and at completion of
chemo-radiation) were collected. Detailed evaluation of pre- and
post-adjuvant chemo-radiation cross-sectional imaging for the
presence and degree of SMV/PV, SMA, celiac axis and hepatic
artery involvement was performed. The size and location of the
pancreatic tumour before and after chemo-radiation was also
noted. The development of metastatic disease was also evaluated.
The end point of analysis included the proportion of patients with
a radiological response and rates of tumour resection. A single,
body imaging radiologist (S.W.) reviewed all films to ensure
uniform interpretation. A paired two sample t-test was used to
compare pre- and post- chemo-radiation tumour size, CA 19-9
levels and tumour density in Hounsfield units.
Results
From 2005 to 2008, 16 patients with locally advanced pancreatic
adenocarcinoma were enrolled in a neo-adjuvant chemo-
radiation protocol based on cisplatin, a-interferon, 5-FU and
radiotherapy. The patient and tumour characteristics of this
group are shown in Table 1. The median age of the cohort was 64
years (range 45–78) and 69% of the patients were male. Five
patients out of 16 had an exploratory laparotomy with the inten-
tion of surgical resection and were found to be un-resectable and
were thus included in the study. One patient (Patient 1, Table 1)
did not have clear vascular involvement on the CT scan but was
found to have portal vein involvement on endoscopic ultrasound
and thus was included in the study. The tumour size (P = 0.14), CA
19-9 levels (P = 0.12) and tumour density (P = 0.36) expressed in
Hounsfield units did not significantly change with treatment
(Table 1).
The imaging characteristics and vascular involvement before
and after treatment of the individual patients is presented in
Table 2. Patients were further classified as having a borderline
resectable tumour or locally advanced un-resectable tumour.
Locally advanced un-resectable tumours were those which were
un-resectable based on their vascular involvement characteristics
and did not have the characteristics of a borderline resectable
tumour as defined in the methods section, typically as a result of
arterial encasement. Sixty-two percent of patients at presentation
had borderline resectable tumour characteristics and the remain-
ing were locally advanced un-resectable. Representative imaging
of a resectable pancreatic cancer (not from the current study),
borderline resectable with intra-operative correlation and two
patients with locally advanced un-resectable disease is shown in
figure (Fig. 1). As seen in Tables 1 and 2, none of the 16 patients
had radiological regression and either had stable disease or
disease progression with additional vascular involvement or
development of distant disease. Furthermore, none of the patients
with locally advanced un-resectable cancer had regression of
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disease to render them resectable (Tables 1 and 2). Specifically, no
encased vessels became ‘un-encased’. Out of 10 patients with bor-
derline resectable disease only 5 underwent a resection after neo-
adjuvant therapy (Tables 1 and 2). All these patients had a margin
negative resection. The remaining five patients with borderline
resectable disease were unable to undergo a resection owing to
poor performance status (3 patients), progression of vascular
involvement (1 patient) or because of the development of distant
disease (1 patient) (Table 2). CA 19-9 levels before and after treat-
ments are shown in Table 2. In the subgroup of patients who
underwent a resection (n = 5), one patient had no macroscopic
tumour and had only microscopic disease. The four remaining
patients had persistent macroscopic disease on pathological
examination.
All of the five patients who had an exploratory laparotomy with
the intent of resection before enrolment in this neo-adjuvant
chemo-radiotherapy trial had borderline resectable disease
(Table 2, comment section). Out of these five patients, two under-
went a surgical resection after neo-adjuvant chemo-radiation
therapy, two could not be resected owing to poor performance
status and one had progression of the disease.
Discussion
In the current series of patients with borderline resectable and
locally advanced un-resectable pancreatic cancer, an aggressive
neo-adjuvant treatment regimen11,12 did not lead to radiological
tumour regression. Furthermore, none of the patients with locally
advanced un-resectable pancreatic cancer and only half of the
patients with a borderline resectable tumour eventually underwent
surgical resection. These data suggests that with currently available
chemo-radiation, radiological regression of an un-resectable
locally advanced tumour to one that is surgically resectable is an
unlikely event. Furthermore, CT is not a reliable indicator of
tumour response.Although imaging may not change in response to
neo-adjuvant treatment, patients with borderline resectable
tumours should undergo tumour resection after completion of
neo-adjuvant therapy, in a patient with good performance status
and in the absence of tumour progression. As has been shown, in
spite of the lack of a radiological response, a margin negative
resection can frequently be performed.
The issue of neo-adjuvant therapy for locally advanced pancre-
atic cancer has been addressed in previous studies with mixed
results. White et al.6 retrospectively analysed the data of 25
patients with locally advanced pancreatic cancer who received
neo-adjuvant chemo-radiation. In this study, locally advanced
pancreatic cancer was loosely defined as disease that abutted the
SMV or SMA or involved lymph nodes. In this study, about 10%
of patients had disease regression on imaging and overall only
20% patients underwent a tumour resection. In another previous
study by Wanebo et al.,5 14 patients with locally advanced pancre-
atic cancer were treated with 5-FU, cisplatin and radiation, 11
patients underwent surgical exploration and 9 received a defini-
tive resection thus reporting a success rate of ~80%. However, on
a closer examination, out of 11 patients who eventually under-
went surgery, 2 patients had T2 disease without any vascular
involvement before neo-adjuvant treatment and 4 patients
required an arterial resection which would not be recommended
Table 1 Patient and tumour characteristics
Age in years












Tumour size (mean  SD)
Pre-treatment 3.85  1.92NS (P=0.1423)
Post-treatment 3.39  1.81
Tumour extension at presentation: % (n)
Borderline resectable 62.5% (10)
Locally advanced 37.5% (6)
CA 19-9 levels:
Pre-treatment 1436  772NS (P = 0.12)
Post-treatment 772  220
Tumour density in Hounsfield units
Pre-treatment 60.4  6.5NS (P =0.3698)
Post-treatment 58.2  6.9




Surgical resection of cancer after
neo-adjuvant chemoradiation: % (n)
Yes 31% (5)
No 69% (11)
Patients undergoing surgical resection
classified by tumour extension at
presentation: % (n)
Borderline resectable 50% (5)
Locally advanced 0% (0)
Pathological response in those
undergoing a resection (n = 5)
Macroscopic tumour 4
Microscopic tumour only 1
NS, non-significant.
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routinely. Remarkably, 7 out of 9 patients either had only micro-
scopic disease or no residual cancer in the resected specimen.
Whether the neo-adjuvant therapy provided radiological regres-
sion in this study is unclear. In another retrospective review of
83 patients3 with locally advanced pancreatic cancer who received
neo-adjuvant chemoradiation from 1993–1999 at Memorial
Sloan-Kettering Cancer Center, only 3.4% had a sufficient
radiological response to consider exploration. In this study,
only patients with extensive retropancreatic venous involvement
or encasement of the celiac axis, hepatic artery or SMA were
included. In a recent single institution retrospective review of 215
patients with locally advanced un-resectable pancreatic cancer
treated with gemcitabine-based neo-adjuvant chemo-radiation,
Habermehl et al.13 demonstrated that 90% of the patients had
stable or progressive disease and only about 10% of patients had
a partial response. Whether there was regression of vascular
involvement, the key determinant of resectability in pancreatic
cancer, is unclear. Furthermore, it is intriguing that even although
all patients had un-resectable disease at presentation and that only
10% of patients had a partial response on imaging, up to one-
fourth of these patients underwent a surgical resection. Whether
there was concomitant vascular resection-reconstruction is
also unclear. In another study by Arvold et al.,14 the effect of neo-
adjuvant therapy on the radiological regression and resection
rates of locally advanced pancreatic cancer was studied. In this
study, neo-adjuvant therapy followed by chemo-radiotherapy led
to radiological regression and surgical resection in 30% and 20%
of the patients, respectively. However, whether there was regres-
sion of vascular involvement is unclear and only 10% of patients
in the locally advanced unresectable group could undergo a
resection.
In the present study, none of the 16 patients had radiological
disease regression. If one was to use the RECIST criteria15 the
radiological responses in the present study would be classified
either as progression or stable disease without any partial or com-
plete responses. The fact that five patients with borderline resect-
able disease with continued vascular involvement were taken to
the operating room but only one patient required vascular resec-
tion again highlights that a CT scan may not correctly predict
regression of vascular involvement. Taken together the data from
the present study and from the published literature3,5,6 suggests
that with currently available neo-adjuvant therapy protocol a
radiological response with regression of an un-resectable locally
advanced tumour to one that is surgically resectable, is an unlikely
event.
Recently, a new subgroup of pancreatic cancer has been recog-
nized, namely borderline resectable pancreatic cancer which is
considered unique from resectable as well as locally advanced
un-resectable pancreatic cancer. Borderline resectable pancreatic
cancer is defined as a tumour which has one or more of the
















Before After Before After Before After Before After
1 BR U U A A U U U U Stable Yes Involvement based on EUS and
intra-operative findings
2 LA U U A A E E E E Stable No
3 BR U U A E U A U E Progression No Pre chemo-rad exploration
4 LA E E E E A E E E Progression No
5 LA U U E E A E E E Progression No
6 BR A A A A U U U U Stable Yes Pre chemo-rad exploration
7 BR U U E E U U U U Stable No Development of Malignant ascites
8 LA U U E E U U E E Stable No
9 BR U U E E U U U U Stable No Poor performance status
10 BR U U A A U U U U Stable Yes Excision and replacement of vein.
11 LA U A E E E E E E Progression No
12 BR U U U E U U U U Progression No Pre chemo-rad exploration. Involvement
of base of mesentery precluded
resection on pre-treatment
exploration, Poor performance status
precluded resection after treatment
13 BR A A U U U U U U Stable No Pre chemo-rad exploration. Poor
performance status precluded
resection.
14 LA A A E E E E E E Stable No
15 BR U U A A U U U U Stable Yes Pre chemo-rad exploration
16 BR U U A A U U U U Stable Yes Vein resection
E, encasement; A, abutment; U, uninvolved; BR, borderline resectable; LA, locally advanced; SMA, superior mesenteric artery; NA, not available.
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following criteria: (i) tumour-associated deformity of the SMV
and PV; (ii) abutment of the SMV or PV  180°; (iii) short-
segment occlusion of the SMV or PV amenable to resection and
venous reconstruction; (iv) short-segment involvement of the
hepatic artery or its branches amenable to resection and recon-
struction; and (v) abutment of the SMA <180°.10 Recognition of
this group of patients is important as the pancreatic resection in
this unique subgroup of patients, although technically possible, is
associated with a high likelihood of R1 and R2 resections. Current
guidelines recommend neo-adjuvant therapy followed by surgery
to improve the likelihood of a margin negative resection.8,16 As
discussed before, and seen in this study, radiological tumour
regression in response to neo-adjuvant therapy is an unlikely
outcome. However, a pathological response to neo-adjuvant
therapy has been described and may facilitate a margin negative
resection. In the study from MD Anderson Cancer Center,8 56% of
(a)  
(d)  (e)  
(b)  (c)  
Figure 1 Representative imaging characteristics of patients with resectable, borderline resectable and locally advanced un-resectable
pancreatic cancer. (a) Patient with resectable pancreatic cancer. The bold arrow indicates a hypodense mass. Small arrows indicate the
superior mesenteric vein (SMV)/ superior mesenteric artery (SMA), both of which have a clear fat plane around them. (b) A patient with
borderline resectable pancreatic cancer. The bold arrow indicates the site where the tumour involves the left side of the portal vein (PV). (c)
Intra-operative picture of a borderline resectable tumour involving the PV. This tumour required the resection of the PV. (d) A locally advanced
un-resectable tumour encasing the celiac axis depicted by a bold arrow. (e) Locally advanced un-resectable pancreatic cancer encasing the
SMA depicted by a bold arrow
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the patients who underwent a pancreatectomy after neo-adjuvant
therapy demonstrated a partial pathological response (<50%
viable tumour). In our series, out of five patients who underwent
a resection, one patient had no macroscopic tumour and had only
microscopic disease on pathological examination. Since the radio-
logical and pathological response may not correlate, all patients
with borderline resectable pancreatic cancer who do not show
disease progression and can tolerate the surgical procedure should
undergo exploration with the intent of a R0 resection.
Given the discrepancy between the radiological and pathologi-
cal response, functional imaging techniques such as positron
emission tomography (PET) may have a role in monitoring the
response to neo-adjuvant therapy. In a recent study by Patel et al.17
evaluating the effect of gemcitabine, docetaxal and capecitabine-
based neo-adjuvant chemo-radiation on resectability and imaging
characteristics of patients with borderline resectable pancreatic
cancer, there was marked reduction in the standard uptake value
(SUV) on PET. The SUV max on PET scan did not correlate
significantly with tumour size as measured by the CT scan. Fur-
thermore, patients who underwent a resection had minimal
residual disease on pathological analysis. In another study, out of
nine patients undergoing18 FDG-PET imaging before and after
neoadjuvant chemoradiation, four had evidence of tumour
regression by PET. These four patients went on to undergo resec-
tion of their tumour and histological analysis demonstrated
20–80% tumour necrosis in the surgical specimen. Of note, the
CT was unable to detect any response to neo-adjuvant therapy in
this group. Based on these limited data, a PET scan may have a role
in following the tumour response to therapy and should be
included in future studies and trials of neo-adjuvant therapy in
pancreatic cancer.
Another common theme, which emerges on close review of the
literature on neo-adjuvant therapy in locally advanced pancreatic
cancer, is the absence of a standard definition of locally advanced
pancreatic cancer. If the results from various studies and trials are
to be comparable it is imperative that a standard definition of
locally advanced pancreatic cancer needs to be employed. It is
logical to separate patients with locally advanced pancreatic
cancer into borderline resectable pancreatic cancer8,16 and locally
advanced unresectable disease. Given that borderline resectable
pancreatic cancer patients are technically resectable and neo-
adjuvant therapy improves the likelihood of a margin negative
resection, it is reasonable to include these patients in trials of
neo-adjuvant therapy. However, given that disease regression with
neo-adjuvant therapy is unlikely, the rational of including locally
advanced unresectable pancreatic cancer in a trial of neo-adjuvant
therapy is unclear. Until more effective therapies are available
these patients should probably be considered for palliative chemo-
therapy only.
This study is limited by the small sample size and the number of
patients eventually undergoing surgery thus limiting the sub-
group of patients in whom the radiological response could be
correlated with the intra-operative and histological findings.
However, we are able to provide detailed analysis of vascular
involvement by a single, fellowship-trained, body imaging radi-
ologist who specializes in the evaluation of pancreatic disease. In
this way, meticulous assessment of vascular involvement could
be performed according to currently recognized, standardized
definitions of ‘borderline resectable’ and ‘locally advanced
un-resectable’ disease. Even although the neo-adjuvant chemo-
radiation regimen used in the present study has been shown to be
equally if not more effective as compared with contemporary
regimens,18,19 the possibility that the low rates of regression of
vascular involvement observed in the present study is as a result of
the use of a non-standard neo-adjvuant protocol cannot be ruled
out.
In summary, these data suggest that with currently available
adjuvant therapy, regression of an un-resectable locally advanced
tumour to one that is surgically resectable is an unlikely event.
Consideration may be given to functional imaging modalities
such as PET to follow the tumour response to neo-adjuvant
therapy. Future clinical trials of neo-adjuvant therapy in pancre-
atic cancer should continue to focus on borderline resectable pan-
creatic cancer, which is the group most likely to benefit from a
neo-adjuvant approach. Patients with borderline resectable pan-
creatic cancer, in the absence of disease progression, should be
routinely explored after neo-adjuvant therapy as imaging may
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